Analysis of the value of rabeprazole combined with anti Helicobacter pylori therapy for gastric ulcers
Objective To discuss the value of rabeprazole combined with anti Helicobacter pylori therapy for gastric ulcers.Methods 108 patients with gastric ulcers were randomly divided into a control group(n=54,omeprazole combined with amoxicillin treatment)and a study group(n=54,rabeprazole combined with anti Helicobacter pylori therapy).The clinical indicators,treatment effect,inflammatory factors and adverse reactions were compared between the two groups.Results The study group interleukin-1β(IL-1β)of(0.17±0.03)ng/ml,gastrin-releasing peptide(GRP)of(2.96±0.8)μg/ml and gastrin(GAS)of(75.23±4.71)ng/L,which were lower than(0.34±0.02)ng/ml,(6.35±1.36)μg/ml and(93.31±5.48)ng/L in the control group;the study group had higher somatostatin(SS)of(46.05±3.67)ng/L than(37.98±2.58)ng/L in the control group(P<0.05).The total effective rate of the study group was 98.15%,which was significantly higher than 87.04%of the control group(P<0.05).After treatment,the study group had tumor necrosis factor-α(TNF-α)of(8.10±0.60)pg/ml,interleukin-6(IL-6)of(28.50±1.40)pg/ml and interleukin-10(IL-10)of(12.20±1.60)ng/L,which were significantly lower than(8.90±0.80)pg/ml,(30.30±1.70)pg/ml and(13.20±1.30)ng/L in the control group(P<0.05).The incidence of adverse reactions in the study group was 5.56%,which was lower than 18.52%in the control group(P<0.05).Conclusion The combination of rabeprazole and anti Helicobacter pylori therapy has a significant therapeutic effect on gastric ulcer patients.
万方数据
维普
